Skip to main content

Advertisement

SpringerLink
Log in

Successful retreatment with 3-week rituximab-bendamustine with high-dose dexamethasone in patients with relapsed/refractory mantle cell lymphoma

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Barista I, Romaguera JE, Cabanillas F (2001) Mantle-cell lymphoma. The Lancet Oncology 2:141–148

    Article  CAS  PubMed  Google Scholar 

  2. Bernard M, Gressin R, Lefrere F, Drenou B, Branger B, Caulet-Maugendre S, Tass P, Brousse N, Valensi F, Milpied N, Voilat L, Sadoun A, Ghandour C, Hunault M, Leloup R, Mannone L, Hermine O, Lamy T (2001) Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype. Leukemia 15:1785–1791

    Article  CAS  PubMed  Google Scholar 

  3. Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grunhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Durk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W (2013) Study group indolent L: Bendamustine plus rituximab versus chop plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381:1203–1210

    Article  CAS  PubMed  Google Scholar 

  4. Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, Hallman DM, Munteanu M, Chen L, Burke JM (2014) Randomized trial of bendamustine-rituximab or r-chop/r-cvp in first-line treatment of indolent nhl or mcl: the bright study. Blood 123:2944–2952

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Becker M, Tschechne B, Reeb M, Schwinger U, Bruch HR, Frank M, Strassl L (2015) Bendamustine as first-line treatment in patients with advanced indolent non-hodgkin lymphoma and mantle cell lymphoma in german routine clinical practice. Ann Hematol 94:1553–1558

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Ogura M, Ishizawa K, Maruyama D, Uike N, Ando K, Izutsu K, Terui Y, Imaizumi Y, Tsukasaki K, Suzuki K, Izumi T, Usuki K, Kinoshita T, Taniwaki M, Uoshima N, Suzumiya J, Kurosawa M, Nagai H, Uchida T, Fukuhara N, Choi I, Ohmachi K, Yamamoto G, Tobinai K (2017) Japanese Bendamustine Lymphoma Study G: bendamustine plus rituximab for previously untreated patients with indolent b-cell non-hodgkin lymphoma or mantle cell lymphoma: a multicenter phase ii clinical trial in Japan. Int J Hematol 105:470–477

    Article  CAS  PubMed  Google Scholar 

  7. Rummel M, Kaiser U, Balser C, Stauch M, Brugger W, Welslau M, Niederle N, Losem C, Boeck HP, Weidmann E, von Gruenhagen U, Mueller L, Sandherr M, Hahn L, Vereshchagina J, Kauff F, Blau W, Hinke A, Barth J (2016) Study Group Indolent L: Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. The Lancet Oncology 17:57–66

    Article  CAS  PubMed  Google Scholar 

  8. Czuczman MS, Goy A, Lamonica D, Graf DA, Munteanu MC, van der Jagt RH (2015) Phase ii study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings. Ann Hematol 94:2025–2032

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria

    Wolfgang Lamm, Barbara Kiesewetter, Hannah Puhr & Markus Raderer

  2. Department of Medicine III, Clinical Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria

    Werner Dolak

  3. Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria

    Marius E. Mayerhöfer

Authors
  1. Wolfgang Lamm
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Barbara Kiesewetter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hannah Puhr
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Werner Dolak
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marius E. Mayerhöfer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Markus Raderer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wolfgang Lamm.

Ethics declarations

All authors gave their informed consent for this study.

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lamm, W., Kiesewetter, B., Puhr, H. et al. Successful retreatment with 3-week rituximab-bendamustine with high-dose dexamethasone in patients with relapsed/refractory mantle cell lymphoma. Ann Hematol 98, 1519–1520 (2019). https://doi.org/10.1007/s00277-018-3588-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-018-3588-y

Search

Navigation